CliffBio
small molecule

OXLUMO

LUMASIRAN SODIUM

Loss of exclusivityNovember 2038latest FDA-listed patent expiry
CompanyAlnylam Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameOXLUMO
Active ingredientLUMASIRAN SODIUM
StrengthEQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalNovember 2020
Marketing statusRX

Listed patents

PatentExpiresType
11261447November 2038substance, product
11446380October 2035substance, product
10478500October 2035substance, product
10612027August 2035substance, product
10612024August 2035substance, product
11401517August 2035substance, product
9828606December 2034substance, product
11060093December 2034substance, product
10465195December 2034substance, product
10435692December 2034use U-2995
10487330December 2034substance, product
8106022December 2029substance, product
8828956December 2028substance, product
10131907August 2028substance, product

Regulatory exclusivity

CodeExpires
ODE-415October 2029
ODE-339November 2027

More from Alnylam Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OXLUMO patent cliff — loss of exclusivity November 2038 | CliffBio